We performed a meta-analysis of studies evaluating the effect of intensive glucose control on major adverse cardiovascular events in patients with type 2 diabetes from 1990 to 2009. A search of the published literature and the Cochran Central Register for Controlled Trials was performed using pre-specified inclusion criteria consisting of randomised controlled trials evaluating intensive glycaemic control and reporting the individual endpoints of all-cause mortality, nonfatal myocardial infarction, and non-fatal stroke. Incident rate ratios for these endpoints were calculated using standard meta-analytic techniques of pooled data from eligible trials. Six reports from four randomised trials including 27,544 patients met the pre-specified inclusion criteria. Mean follow-up was 5.4 years; haemoglobin A 1C at study end was 6.6% vs. 7.4% in patients randomised to intensive compared with conventional glucose control. Intensive glucose control did not affect the incident rate ratio for all-cause mortality (1.01, 95% confidence interval 0.86-1.18, p=0.54) or stroke (1.02, 95% confidence interval 0.88-1.20, p=0.62). However, there was a statistically significant 14% reduction in nonfatal myocardial infarction in patients randomised to intensive glucose control (0.86, 95% confidence interval 0.77-0.97, p=0.015). Although intensification of glucose control did not affect mortality or non-fatal stroke, the risk for non-fatal myocardial infarction was significantly reduced in patients with type 2 diabetes.
Introduction
Diabetes mellitus is a common, complex, and chronic disease presently afflicting an estimated 24 million adults in the United States. 1 The prevalence of diabetes continues to increase, notably among young adults, adolescents, and children who have an estimated 1 in 3 lifetime risk of developing diabetes. 2 The principal morbidity and mortality associated with diabetes is driven by atherosclerotic vascular disease, with diabetes in middle-aged and older adults considered a coronary heart disease risk equivalent. 3 Primary prevention of cardiovascular disease in individuals with diabetes presently consists of controlling traditional risk factors, including weight, blood pressure, and lipids, often with more aggressive therapeutic targets than the non-diabetic population. [4] [5] [6] [7] Although intensive glucose control has been demonstrated to reduce microvascular trials differed to some degree, all included myocardial infarction, stroke, and all-cause mortality. [9] [10] [11] Since uncertainty remains regarding the influence of intensification of glucose control on the risk of cardiovascular events, we performed a systematic review and analysis of available randomised controlled studies evaluating effect of intensive compared with standard glucose control in patients with type 2 diabetes mellitus on cardiovascular outcomes, comprising the individual outcomes of death, non-fatal myocardial infarction, and non-fatal stroke.
Methods

Inclusion criteria
We searched for articles published in the English language from 1990 to March 2009 that reported results evaluating the effect of intensive versus standard glucose control on MACE in patients with type 2 diabetes. Studies were identified using the following: 1) National Library of Medicine PubMed database 12 using the Medical Subject Heading (MeSH) key words diabetes mellitus, type 2; blood glucose; follow-up studies and human; 2) Cochrane Central Register for Controlled Trials; 13 3) Cochrane Database for Systematic Reviews; 14 4 ) ClinicalTrials. gov 15 using the terms 'diabetes', 'cardiovascular', and 'randomised'. Pre-specified inclusion criteria for candidate studies consisted of: 1) prospective randomised controlled trials of persons with type 2 diabetes mellitus; 2) a stated scientific objective to evaluate the effect of intensive glucose control compared with standard therapy on cardiovascular events; 3) trials reporting the individual MACE endpoints of all-cause mortality, non-fatal myocardial infarction, and non-fatal stroke; 4) studies reporting follow-up ≥ 1 year. Exclusion criteria consisted of: 1) glucose-lowering treatment administered during acute myocardial infarction; 2) randomised controlled trials including type 1 diabetic patients; 3) studies not reporting individual endpoints of all-cause mortality, nonfatal myocardial infarction, and non-fatal stroke.
Study selection
Bibliographic references of 618 articles were manually reviewed by two investigators (JH, KK) for relevance. Full text manuscripts were obtained on 38 studies believed to meet the inclusion criteria and were reviewed by a third investigator (SM) for final inclusion. Six reports from four randomised controlled trial programmes met the pre-specified inclusion criteria: 1) United Kingdom Prospective Diabetes Study (UKPDS 33) 8 and UKPDS 34, 16 2) Action to Control Cardiovascular Risk in Diabetes (ACCORD), 10 3) Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE), 11 4) Veteran's Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VACSDM) feasibility trial 17 and Veteran's Affairs Diabetes Trial (VADT). 9 Details of each have been reported previously. In brief, patients in UKPDS were randomised to intensive glucose control with sulphonylurea or insulin compared with dietary intervention in the conventional therapy group. The goal of intensive glycaemic reduction was a fasting plasma glucose < 6.05 mmol/L. The primary outcome was any aggregate diabetes-related endpoint, consisting of sudden death, hyperor hypoglycaemia-related death, fatal or non-fatal myocardial infarction, angina, heart failure, stroke, renal failure, amputation, vitreous haemorrhage, retinal photocoagulation, blindness, or cataract extraction; diabetes-related death due to myocardial infarction, stroke, hyper-or hypoglycaemia, peripheral vascular or renal disease, or sudden death; or allcause mortality. An important aspect of the UKPDS was the expressed objective to control glucose. In UKPDS 34, metformin was included as an additional active treatment group compared with UKPDS 33. There were 342 overweight patients eligible to undergo further randomisation to intensive glucose control with metformin in UKPDS 34 that were included this meta-analysis. In ACCORD, patients with type 2 diabetes and glycated haemoglobin ≥ 7.5% were randomised to intensive (target glycated haemoglobin < 6%) or standard glucose control (7-7.9%), with therapy to achieve glucose lowering at the discretion of the treating physician. The primary outcome was a composite of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death. The ADVANCE trial enrolled patients with type 2 diabetes and a median glycated haemoglobin level of 8.1% to intensive glucose control (≤ 6.5%) or standard therapy (7.0-7.9%). The primary outcome was a combined macrovascular and microvascular composite (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke and new or worsening nephropathy or retinopathy). The VACSDM feasibility trial randomised 153 male subjects with type 2 diabetes to standard glucose control consisting of once-daily insulin or intensive control with multiple insulin injections and glipizide as needed to maintain normoglycaemia. Primary endpoints consisted of myocardial infarction, congestive heart failure, stroke, amputation, cardiovascular mortality, angina, transient ischaemic attack, revascularisation (surgical or percutaneous), or new claudication. VADT, which included 1,791 US military veterans with type 2 diabetes, defined intensive glucose control as an absolute 1.5% reduction in glycated haemoglobin compared with the standard therapy group. The primary outcome was the occurrence of composite major cardiovascular events, including cardiovascular death, myocardial infarction, surgery for atherosclerotic disease, stroke, congestive heart failure, or amputation for ischaemic gangrene or inoperable coronary disease.
Endpoints
Pre-specified endpoints for this analysis were all-cause mortality, non-fatal myocardial infarction, and non-fatal stroke. Table 1 defines cardiovascular events from each included trial. 
Statistical analysis
Data abstracted from eligible studies consisted of age, sex, duration of diabetes, change in haemoglobin A 1C (HbA 1C ) level, proportion of patients with history of coronary artery disease, anti-diabetic agents used in the comparator and active treatment arms, and treatment/study duration. In trials reporting outcomes from the same patient population (UKPDS 33 and 34), the report with the greater number of patients rather than the longest follow-up was used. Composite HbA 1C values were calculated from reported results using weighted averages from the baseline sample size. Incidence rates of non-fatal myocardial infarction, nonfatal stroke, and all-cause mortality in each treatment arm were calculated by dividing the number of events by the number of person-years of follow-up. Incidence rate ratios (IRRs) were calculated for each endpoint by dividing the incidence in the intensive by the conventional arm. Heterogeneity was tested using the Cochran statistic. IRRs for non-fatal stroke and myocardial infarction (p>0.05 for Cochran statistic) were combined across trials using a fixed-effects model and were weighted using the inverse of the variance of the logarithmic IRR for each study. In failed tests of heterogeneity (p≤0.05) a random-effects model was implemented, and the I 2 statistic was calculated to reweight the effects accordingly. Overlap in the conventional arm of UKPDS 33 and 34 was treated by subtracting the number of events and patients included in the conventional arm of UKPDS 34 from UKPDS 33 to avoid double counting of events and weighting. 18 Tests of publication bias were performed using funnel plots and Egger's test for funnel plot asymmetry. 19 A sensitivity analysis for non-fatal myocardial infarction was performed excluding the data from the ACCORD trial, since it was discontinued prematurely due to excess mortality.
Results are presented as IRRs with 95% confidence intervals (CIs) in a forest plot. All analyses were performed using the rmeta library in R version 2.8.1 (R Project for Statistical Computing, Vienna, Austria).
Results
There were 27,544 patients with 148,371 patient-years of follow-up included in the analysis (14,740 patients with 84,926 patient years of follow-up in the intensively-treated arm and 12,804 patients with 63,446 patient years of follow-up in the conventional group). Table 2 summarises general trial characteristics. The mean follow-up was 5.4 years. Final HbA 1C values in the intensive and conventional groups were 6.6% and 7.4%, respectively. Table 3 summarises selected trial and patient characteristics, including glucose-lowering treatment available to study participants.
The results of intensive glucose-lowering strategy on MACE are summarised in Table 4 and Figure 1 . The annual incidence of all-cause mortality in the study population was 1.65 per 100 person-years. In total, there were 1,399 deaths from all causes in the intensive group and 1,047 in the conventional group. Intensive glucose control did not result in a statistically significant difference in all-cause mortality (IRR 1.01, 95% CI 0.86-1.18, p50.93). In two trials there were differing effects on mortality in intensively-treated patients. There was an increase in all-cause mortality in the intensive group in ACCORD (IRR 1.27, 95% CI 1.05-1.53, p50.01) but a 33% reduction in UKPDS 34 compared with the conventional group (IRR 0.67, 95% CI 0.47-0.95, p50.013).
The annual incidence of non-fatal stroke in the study population was 0.56 per 100 person-years. There were 474 events in intensively-treated compared with 363 events in conventionally-treated patients and no statistical difference in the IRR associated with intensive treatment (IRR 1.02, 95% CI 0.88-1.20, p50.76). Individually, none of the trials demonstrated a significant effect of intensive treatment on the incidence rate of stroke. The annual incidence of non-fatal myocardial infarction in the study population was 0.82 per 100 person-years. There were 640 events in patients randomised to intensive glucose control and 579 events in the conventional group.
Overall, intensive glucose control was associated with a statistically significant 14% reduction in non-fatal myocardial infarction (IRR 0.86, 95% CI 0.77-0.97, p50.015). Results were qualitatively similar in sensitivity analysis when data from the ACCORD trial were excluded, with 454 events in the intensive compared with 344 events in the conventional group (IRR 0.91, 95% CI 0.79-1.06, p50.11).
Data on cardiovascular mortality were reported for only four studies (ACCORD, ADVANCE, VADT, and VACSDM). Funnel plots for all-cause mortality, non-fatal stroke, and myocardial infarction showed no visual evidence for deviation in symmetry. Egger's test of asymmetry revealed no publication bias for all-cause mortality, non-fatal stroke, and myocardial infarction (p50.85, 0.99, and 0.92, respectively).
Discussion
Pooled results from six clinical trials of patients with type 2 diabetes randomised to intensive or conventional glucose control suggest that: 1) intensive glucose control was associated with a statistically significant reduction in HbA 1C values compared with conventional glucose control. The mean follow-up haemoglobin HbA 1C for these trials was 6.6% in the intensive group vs. 7.4% in the conventional group; 2) there was no significant effect observed on the incidence of all-cause mortality (2,446 evaluable events), cardiovascular mortality (844 evaluable events), or non-fatal 
Selection criteria
Two overarching unresolved clinical questions remain regarding the cardiovascular effects of glucose management in patients with type 2 diabetes. First, what is the role of intensifying glucose control per se for reducing cardiovascular risk independent of consideration of specific effects of drugs or strategies used to achieve such control? Second, what are the specific cardiovascular efficacy and safety profiles for current and emerging glucose-lowering therapies alone and in combination, including but extending beyond the influence of their glycometabolic effects? The present meta-analysis was performed to address the former but not the latter question. That is, our inclusion criteria were predicated on elucidating the relationship between strategies of more intensive compared with less intensive glucose control and MACE, independent of the drugs and strategies used to achieve target control, rather than the effects of any specific glucose-lowering drug, class, or combination. For that purpose, we did not attempt to account for differences in glucose-lowering therapies between either trials or comparison groups, and only clinical trial programmes with the stated scientific objective of evaluating the effect of intensification of glucose control on clinical outcomes that specifically included assessment of MACE were included. Our results are consistent with a recently published report by Ray et al., 20 with some noted methodological differences. First, unlike the prior publication, we did not include data from the PROactive trial, 21 since that trial compared a targeted dose of pioglitazone versus placebo, with titration independent of glucose control and a protocol objective to maintain glycaemic equipoise in the comparator groups; these same considerations prompted our exclusion of the published results from the RECORD trial. 22 Second, in the prior publication, data from UKPDS 33 and 34 were combined for analytic purposes, which has key methodological limitations given a) the markedly different inter-group differences in achieved glucose control between the studies, and b) the heterogeneity of effects on MACE between the component studies of the UKPDS programme.
In light of recent work suggesting differential effects of thiazolidinediones on MACE 23, 24 and persistent uncertainty with regard to other classes of glucose-lowering drugs not yet individually evaluated for cardiovascular effects, the evaluation of such considerations remains an important objective of ongoing research but is not possible in this meta-analysis. In the present work, potential confounding by differential treatment effects of individual drugs was attenuated to some degree in the trials with active comparator arms for glucose control (ACCORD, ADVANCE, and VADT) by making the same drugs available for use in either of the treatment groups, although the principal parameter of randomisation across trials was more versus less intense target HbA 1C . While limiting potential confounding by specific drug effect to some degree, it does not entirely eliminate it, as those patients randomised to more intensive targets inevitably received higher doses of drugs used as well as a higher frequency of each individual drug class compared with the conventional control arms. For example, in the ACCORD trial, participants were treated with a broad range of oral antihyperglycaemic drugs, including metformin, insulin secretagogues (sulphonylureas, glimepriride, repaglinide), thiazolidinediones (rosglitazaone), α-glucosidase inhibitors, and incretin mimetics (exenatide). Expectedly, although each of the drugs was similarly available for use in both of the ACCORD randomised treatment arms, the frequency of use of each drug class was higher among patients randomised to intensive glucose control, including metformin (94.7% vs. 86.9%), insulin secretagogues (86.6% vs. 73.8%), thiazolidinediones (91.7% vs. 58.3%), α-glucosidase inhibitors (23.2% vs. 5.1%), and incretin mimetics (17.8% vs. 4.9%). These patients were also more likely to be taking multiple classes of agents (3 classes: 59.1% vs. 32.8%; 4 or 5 classes: 10.5% vs. 2.1%). Similarly, in the ADVANCE trial, each oral antihyperglycaemic drug class was more frequently used in the intensive group, including metformin (73.8% vs. 67.0%), sulphonylurea (89.0% vs. 56.7%), thiazolidinediones (16.8% vs. 10.9%), and α-glucosidase inhibitors (19.1% vs. 12.6%). The available classes of oral agents in VADT for both randomised arms included rosiglitazone, metformin, and glimepiride. In both treatment groups, patients with a body mass index ≥ 27 kg/m 2 were started on metformin and rosiglitazone; those < 27 kg/m 2 were started on glimepiride plus rosiglitazone. Patients in the intensive group were started on maximal doses, compared with half the maximal doses in the control group. Before any change in oral medication, insulin was added for patients in the intensive group who did not achieve a glycated haemoglobin level < 6%. In UKPDS 33 and 34 a policy of intensive glucose control was compared with initial dietary intervention. As expected, patients in the intensive arm were more often treated with sulphonylurea and insulin (UKPDS 33) and metformin (UKPDS 34) based primarily on the randomised treatment assignment. Admittedly, differential treatment effects (favourable or unfavourable) associated with any specific drug or class may have materially contributed to the outcomes in these trials. However, the analysis of such effects of non-randomised treatment is complex, requires analysis of patient-level data, and is beyond the scope of the present study. It is important to note that the treatment strategies within each of the selected trials for the present study affords analysis of the effects of intensifying glucose control on the background of prevalently used drugs and combinations prevalent in contemporary practice, therefore yielding 'pragmatic', clinically relevant comparisons.
Mortality and myocardial infarction
The risk of premature mortality and nonfatal myocardial infarction are highly relevant when considering long-term medical therapy for patients with type 2 diabetes. Our work demonstrates a 14% reduction in the incidence of nonfatal myocardial infarction, with no discernible effect on overall mortality or non-fatal stroke associated with strategies of more intense glucose control, while at the same time observing an adverse signal for a non-significant 15% greater risk of cardiovascular mortality in pooled results from four of the six included trials that reported this component outcome. While the ACCORD trial was terminated prematurely due to increased risk for all-cause mortality in the intensive group, it should be noted the trial mandated very aggressive glycaemic control, with a target HbA 1C of < 6%. On average, ACCORD subjects had a longer duration of diabetes and achieved rapid lowering of HbA 1C . The mechanism underlying the increased risk of death in ACCORD participants has been discussed in detail 10,25 but remains unknown. Importantly, the increased all-cause mortality signal from the ACCORD trial was not evident in either any of the other studies included in the present analysis or our pooled analysis, with the point estimate of adverse risk for fatal MI observed in ACCORD similarly observed as a non-significant trend in VADT.
While our results suggest a modest effect of intensive glucose control on prevention of myocardial infarction, these results should be interpreted with caution based on the low annualised incidence rate observed in the pooled trials (0.82%), and countered by the trend toward increased CV mortality. This raises three important considerations. First, such a low event rate would tend to compromise statistical power and precision. However, the large sample sizes of these trials and the relatively long study duration yielded a substantive number of events to analyse, reflected by the narrow confidence intervals of the pooled analyses, thus largely abrogating this concern. Second, the overall observed event rates are about one-half of that expected in the context of 'coronary disease equivalent' risk associated with diabetes, thereby potentially compromising the generalisability of the pooled results due to selection biases of the studies analysed. However, given the increasingly prevalent use of other cardiovascular risk-reducing therapies in the setting of diabetes, the observed rates may very well reflect contemporary practice and therefore be acceptably generalisable. Lastly, given the small absolute risk reduction estimate, one would have to treat 629 patients for 5.4 years to prevent one myocardial infarction, an extremely unfavourable number needed to treat and inevitably cost-prohibitive even for the least expensive of therapies. However, this interpretation should be considered with caution, given that the principal imperative for glycaemic control in patients with diabetes remains the prevention of microvascular disease, independent of MACE effects.
Primum non nocere
It is of some interest to consider the present observations in the context of the evolving regulatory landscape for diabetes drugs. Based on a paucity of clinical outcomes data on cardiovascular effects, individual trials failing to demonstrate superiority with regard to cardiovascular endpoints, and safety signals for observed cardiovascular risk for selected diabetes drugs, 26, 27 the regulatory landscape in this therapeutic area has recently undergone a rapid evolution. The focus of evaluation has shifted dramatically from demonstration of glucose lowering to now include demonstration of cardiovascular safety. In that context, guidance for the development and registration of glucose-lowering drugs has recently been updated by the US Food and Drug Administration (FDA) 28 and is forthcoming from the European Medicines Agency (EMEA). The FDA has prescribed iterative thresholds for assessment of cardiovascular safety for glucose-lowering drugs prior to and after approval, such that by the time of registration, an excess of cardiovascular risk of 80% or more has been a threshold of exclusion (i.e. a non-inferiority upper confidence limit [UCL] of < 1.8), with the ultimate requirement to exclude excess cardiovascular risk of ≥ 30% (UCL < 1.3) required to maintain approval. Considering each of the present trials and pooled data in that context, each of the trials analysed in the present study (excepting the small VACSDM pilot study) would individually achieve such thresholds, as would each of the present component event meta-analyses. While the individual trials were 'negative' on the basis of not achieving statistical superiority for the primary endpoints, all would be considered to represent 'approvable' strategies based on their 95% UCL, excluding the FDA-defined threshold of unacceptable cardiovascular harm.
Limitations
First, this work does not rule out a complex interplay between mortality and prevention of myocardial infarction, as suggested by the ACCORD trial observations based on 460 mortal events. However, it is reassuring that there was no increased signal for mortality associated with intensive treatment in any of the other 5 trials analysed nor in the pooled results comprising over 2,400 mortality events, with UKPDS 34 demonstrating a mortality benefit associated with metformin therapy. Subanalyses from ACCORD and VADT have implied that the estimated benefits were greatest in those with shorter disease duration and/or better glucose control at study entry, suggesting that earlier intensive intervention may yield more favourable effects on MACE. While limited to hypothesis generation that will require trial confirmation, these post hoc analyses are supported by the primary data from the UKPDS studies, enrolling patients at the time of diabetes diagnosis, and by the longterm post-trial follow-up results from those trials. 25, 29, 30 Of the studies analysed, only the UKPDS systematically enrolled patients early in the course of disease, so that the present results may not apply to those with shorter diabetes duration. In addition, given the distribution of absolute treatment effects and levels of HbA 1C achieved, we are unable to provide specific patient HbA 1C treatment goals, with factors in addition to net cardiovascular disease effect contributing, such as risk of and tolerance to hypoglycaemia as well as quality of life considerations. The significance of these findings should be interpreted with caution since five of the six included trials individually failed to show a beneficial effect of treatment intensification on mortality, potentially suggesting that myocardial infarct events in patients randomised to intensive therapy were more likely to be fatal. Finally, patient-level data were not available in the present meta-analysis, precluding the ability to perform time-to-event analyses or to adjust for differences in baseline characteristics or differences in patient mix, along with other noted limitations of using summary-level data in meta-analysis. Formation of a collaborative group to pool available data from intensive glucose-lowering trials would be beneficial in determining differences between subgroups.
Conclusions
In a meta-analysis of summary-level data from six randomised controlled trials of intensification of glycaemic control among patients with diabetes, we found no statistically significant effect on mortality from cardiovascular or any cause or non-fatal stroke, but a significant 14% relative reduction in the rate of non-fatal myocardial infarction in patients randomised to intensive glucose control.
